东诚药业
(002675)
| 流通市值：91.88亿 | | | 总市值：101.92亿 |
| 流通股本：7.43亿 | | | 总股本：8.25亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,585,343,598.9 | 1,785,010,462.33 | 850,500,484.35 | 3,582,955,427.13 |
| 营业收入 | 2,585,343,598.9 | 1,785,010,462.33 | 850,500,484.35 | 3,582,955,427.13 |
| 二、营业总成本 | 2,195,344,480.18 | 1,516,027,277.89 | 764,778,405.24 | 3,034,644,757.32 |
| 营业成本 | 1,452,702,536.75 | 988,951,730.42 | 447,006,265.63 | 2,044,375,219.68 |
| 税金及附加 | 24,734,098.79 | 16,446,527.25 | 7,751,517.91 | 29,188,323.08 |
| 销售费用 | 406,101,183.28 | 302,707,746.62 | 165,018,368.72 | 566,119,925.35 |
| 管理费用 | 185,818,632.89 | 132,851,439.31 | 77,572,608.92 | 225,289,332.56 |
| 研发费用 | 124,762,533.47 | 83,932,661.39 | 47,321,769.47 | 163,520,492.52 |
| 财务费用 | 1,225,495 | -8,862,827.1 | 20,107,874.59 | 6,151,464.13 |
| 其中:利息费用 | 31,821,269.02 | 21,157,799.59 | 10,961,264.49 | 58,641,109.4 |
| 其中:利息收入 | 8,774,744.52 | 6,051,911.4 | 3,406,131.54 | 13,196,918.62 |
| 加:公允价值变动收益 | - | - | - | 401,084.93 |
| 加:投资收益 | 743,753.98 | -6,916,195.45 | -7,055,328.88 | -39,613,778.6 |
| 资产处置收益 | 35,761.58 | 37,401.84 | 3,261.96 | 133,566.65 |
| 资产减值损失(新) | 185,896.96 | - | - | -80,290,454.57 |
| 信用减值损失(新) | 5,026,555.29 | 2,823,860.47 | -1,562,467.8 | -5,150,017.73 |
| 其他收益 | 17,472,570.12 | 13,102,957.54 | 9,589,346.86 | 24,460,463.65 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 413,463,656.65 | 278,031,208.84 | 86,696,891.25 | 448,251,534.14 |
| 加:营业外收入 | 271,159.13 | 221,483.43 | 9,471.27 | 169,929.15 |
| 减:营业外支出 | 831,440.63 | 420,254.41 | 116,004.92 | 2,845,007.17 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 412,903,375.15 | 277,832,437.86 | 86,590,357.6 | 445,576,456.12 |
| 减:所得税费用 | 72,206,741.13 | 54,766,249.96 | 23,675,382.51 | 92,760,034.24 |
| 六、净利润 | 340,696,634.02 | 223,066,187.9 | 62,914,975.09 | 352,816,421.88 |
| 持续经营净利润 | 340,696,634.02 | 223,066,187.9 | 62,914,975.09 | 352,816,421.88 |
| 归属于母公司股东的净利润 | 285,811,541.04 | 184,306,413.58 | 50,106,641.46 | 307,289,459.65 |
| 少数股东损益 | 54,885,092.98 | 38,759,774.32 | 12,808,333.63 | 45,526,962.23 |
| (一)基本每股收益 | 0.35 | 0.22 | 0.06 | 0.38 |
| (二)稀释每股收益 | 0.35 | 0.22 | 0.06 | 0.38 |
| 八、其他综合收益 | -1,887,785.68 | -1,915,485.34 | -2,513,718.76 | 18,467,959.95 |
| 归属于母公司股东的其他综合收益 | -737,757.85 | -2,510,684.79 | -2,463,157.2 | 16,628,331.82 |
| 九、综合收益总额 | 338,808,848.34 | 221,150,702.56 | 60,401,256.33 | 371,284,381.83 |
| 归属于母公司股东的综合收益总额 | 285,073,783.19 | 181,795,728.79 | 47,643,484.26 | 323,917,791.47 |
| 归属于少数股东的综合收益总额 | 53,735,065.15 | 39,354,973.77 | 12,757,772.07 | 47,366,590.36 |
| 公告日期 | 2023-10-27 | 2023-08-24 | 2023-04-29 | 2023-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |